tiprankstipranks
Trending News
More News >

Fate Therapeutics price target lowered to $4 from $5 at Baird

Baird lowered the firm’s price target on Fate Therapeutics (FATE) to $4 from $5 and keeps a Neutral rating on the shares. The firm updated its model following Q1 results which met expectations.

Don’t Miss TipRanks’ Half-Year Sale

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1